PUBLISHER: The Business Research Company | PRODUCT CODE: 1942705
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942705
Desmoplastic small round cell tumor (DSRCT) treatment involves therapies such as surgery, chemotherapy, and radiation aimed at controlling this rare, aggressive cancer and slowing its spread, mainly in the abdomen. These treatments can help shrink tumors, improve survival, and enhance quality of life.
The major treatment types in the desmoplastic small round cell tumor market include immunotherapy, surgical procedures, chemotherapy, and radiotherapy. Immunotherapy is a treatment approach that utilizes the body's immune system to combat diseases, especially cancer. The different drug classes involved include cytotoxic agents, targeted therapies, and immunomodulators, and the primary end users include hospitals, oncology clinics, and ambulatory surgical centers.
Tariffs have influenced the dsrct treatment market by increasing the cost of imported targeted therapy drugs, monoclonal antibodies, and immunotherapy agents. Segments such as immunotherapy and advanced chemotherapeutic drugs are most affected, with regions including north america and europe facing higher import duties. This has led to elevated treatment costs and supply chain adjustments. However, tariffs have also encouraged local manufacturing of therapies and investment in domestic research, which may enhance long-term accessibility and innovation in dsrct treatments.
The desmoplastic small round cell tumor treatment market research report is one of a series of new reports from The Business Research Company that provides desmoplastic small round cell tumor treatment market statistics, including desmoplastic small round cell tumor treatment industry global market size, regional shares, competitors with a desmoplastic small round cell tumor treatment market share, detailed desmoplastic small round cell tumor treatment market segments, market trends and opportunities, and any further data you may need to thrive in the desmoplastic small round cell tumor treatment industry. This desmoplastic small round cell tumor treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The desmoplastic small round cell tumor treatment market size has grown strongly in recent years. It will grow from $4.01 billion in 2025 to $4.35 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to limited treatment options for dsrct, reliance on conventional chemotherapy and surgery, low awareness of rare tumors, inadequate specialized oncology infrastructure, delayed diagnosis of dsrct.
The desmoplastic small round cell tumor treatment market size is expected to see strong growth in the next few years. It will grow to $5.92 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to development of targeted therapies and immunotherapies, integration of ai-driven diagnostics, rising clinical trials for dsrct, expansion of oncology clinics and ambulatory surgical centers, increasing healthcare funding for rare cancers. Major trends in the forecast period include rising adoption of multimodal cancer treatments, increasing focus on rare cancer research and clinical trials, growing investment in targeted therapies and immunotherapy, expansion of specialized oncology centers, enhanced patient support programs and post-treatment care.
The increasing emphasis on personalized medicine is anticipated to support the expansion of the desmoplastic small round cell tumor treatment market going forward. Personalized medicine involves tailoring healthcare approaches based on an individual's genetic profile, lifestyle, and environmental factors, incorporating methods such as pharmacogenomics, targeted therapies, and gene editing. The heightened focus on personalized medicine is driven by advances in genomics, improved treatment outcomes, and the ability to deliver more precise and effective therapies. Personalized medicine enables more effective treatment of desmoplastic small round cell tumor (DSRCT) by aligning therapies with the tumor's unique genetic and molecular characteristics, improving efficacy while reducing adverse effects. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to six approvals in 2022. Consequently, the growing focus on personalized medicine is strengthening momentum in the DSRCT treatment market.
Growing investment in oncology research is expected to drive the growth of the desmoplastic small round cell tumor treatment market going forward. Investment in oncology research continues to rise due to increasing global cancer incidence, advancements in precision medicine, and the growing need for innovative therapies to improve patient outcomes. Oncology research supports the treatment of desmoplastic small round cell tumors by advancing understanding of tumor biology, enabling the development of targeted therapies and improved treatment protocols that enhance clinical outcomes. For example, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government's net spending on research and development increased to £17.4 billion ($22.1 billion) in 2023 from £16.1 billion ($20.45 billion) in 2022, representing an 8.2% increase. Consequently, rising investment in oncology research is fueling growth in the desmoplastic small round cell tumor treatment market.
The increasing number of clinical trials is expected to propel the growth of the desmoplastic small round cell tumor treatment market going forward. Clinical trials involve human participants and are conducted to evaluate the safety and effectiveness of new medical treatments or procedures while generating scientific evidence for human use. The growth in clinical trials is driven by advances in medical research, rising disease burden, regulatory developments, globalization of clinical research, increased patient awareness and advocacy, industry competition, technological progress, and expanding funding opportunities. Clinical trials enable patient access to innovative therapies and support evaluation of new treatment approaches, improving outcomes and advancing the development of targeted and more effective therapies. For example, in December 2025, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported that the number of new industry-sponsored clinical trials initiated in the UK rose by 36% in 2024, increasing to 578 trials from 426 in 2023. As a result, the UK advanced to sixth place globally for phase III trial initiations in 2024, up from eighth place in 2023. Therefore, the growing number of clinical trials is driving the growth of the desmoplastic small round cell tumor treatment market.
Major companies operating in the desmoplastic small round cell tumor treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Zymeworks Inc., Blueprint Medicines Corporation, MacroGenics Inc., Exelixis Inc
North America was the largest region in the desmoplastic small round cell tumor treatment market in 2025. The regions covered in the desmoplastic small round cell tumor treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the desmoplastic small round cell tumor treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The desmoplastic small round cell tumor treatment market includes revenues earned by entities by providing services such as immunotherapy, diagnostic imaging, and post treatment care, including rehabilitation and follow up monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Desmoplastic Small Round Cell Tumor Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses desmoplastic small round cell tumor treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for desmoplastic small round cell tumor treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The desmoplastic small round cell tumor treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.